Mayne Pharma Group (ASX:MYX) said its unaudited revenue for the fiscal 2026 first half came in at AU$212.1 million, down 0.5% from the result it reported in the year-ago period, according to a Thursday Australian bourse filing.

Its unaudited underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) for the period clocked in at AU$28.6 million, down 8% year-over-year from AU$31 million in the first half of fiscal year 2025.

It cited a lower contribution from the women's health segment, as well as additional investment into sales activities, as drivers behind the underlying EBIDTA.